More importantly, CXCL14 inhibitors (such as AMD3465) (37) reduced collagen deposition by 42% in an IPF mouse model (p = 0.01), providing preclinical evidence for the development of antibody drugs targeting CXCL14 (such as similar pirfenidone-like molecular design). Here, CXCL14 is linked to idiopathic pulmonary fibrosis.